Osseo IQ
Chapter 3 · Patient Selection & Medical Risk · §3.4

Diabetes: Perioperative Management

Let glycemic control, not the diagnosis, set the timeline — when to proceed, when to optimize, and when to defer.

Compiled by
Tan Khuu, DDS
Licensed dentist (CA & SC)
Audience
Oral surgeons, prosthodontists, periodontists & residents
Edition
1.0 · June 2026
Reviewed
June 2026 · next review June 2027
Reading time
~16 minutes
Evidence basis
Systematic reviews + meta-analyses + consensus
§3.4.1 — Overview

Control, not diagnosis, governs the decision

Diabetes mellitus is among the most common comorbidities the implant clinician will encounter, and it is also among the most misunderstood. The reflex to treat the label — to regard "diabetic" as a near-contraindication — is not supported by the contemporary literature. What the evidence shows, with notable consistency across systematic reviews and meta-analyses, is that implant outcomes track the degree of glycemic control rather than the diagnosis itself. A patient whose disease is well controlled achieves implant survival statistically indistinguishable from a non-diabetic patient; a patient whose disease is poorly controlled carries a measurable, dose-dependent excess of delayed healing, infection, and peri-implant bone loss.13

The operational consequence is that the perioperative decision turns on a single, objective, retrievable number: the glycated hemoglobin (HbA1c), which reports average glycemia over the preceding two to three months. HbA1c stratifies the patient into one of three bands and, with it, one of three pathways — proceed when control is good, optimize first when control is borderline, or defer elective surgery when control is poor. The HbA1c is read alongside the day-of-surgery capillary glucose, which captures acute hyperglycemia that a months-old average will miss.25

Why control matters mechanistically is developed in the biology chapters, but the headline is worth stating here. Chronic hyperglycemia generates advanced glycation end-products that stiffen collagen and provoke a sustained pro-inflammatory state; it impairs the M1→M2 macrophage transition, blunts angiogenesis, suppresses osteoblast function while favoring osteoclastic resorption, and compromises neutrophil-mediated infection control. These are precisely the steps on which early osseointegration depends, which is why delayed healing and infection dominate the diabetic risk profile and why perioperative glucose and scrupulous anti-infective technique apply across every band.14

Well-controlled diabetes is not a contraindication to implants; the question is never whether the patient is diabetic, but how well the disease is controlled.
◆ Key concept · The three-band gate

A recent HbA1c places the patient in one of three bands. Well-controlled (≤7%) warrants standard care with routine precautions. Moderately controlled (7–8%) — the zone many sources still accept — is generally acceptable but invites optimization before elective surgery and heightened vigilance. Poorly controlled (>8%) calls for deferring elective placement and physician-led medical optimization first. Across all three, confirm an acceptable day-of-surgery glucose and apply rigorous infection control — these are not band-specific, they are universal.

§3.4.2 — Classification

Glycemic control bands and what they predict

Control is graded by HbA1c, and the bands below are the conventional cut-offs used across the implant literature, recognizing that exact thresholds vary among guidelines and that the underlying evidence is heterogeneous. The relationship is best understood as a gradient rather than a cliff: there is moderate evidence of a dose-response trend in which clinical and radiographic peri-implant outcomes decline progressively as HbA1c rises, so a patient at 8.5% is not categorically different from one at 9.5% so much as further along the same curve.3

In the well-controlled band, pooled survival figures sit in the range of roughly 96–97% at one year and remain comparable to non-diabetic cohorts over several years — the basis for treating these patients as standard-risk.2 The moderately controlled band carries a modest, often clinically acceptable excess risk, chiefly of slowed healing; the prudent response is optimization where feasible rather than refusal. The poorly controlled band is where delayed healing, impaired infection control, and accelerated marginal bone loss become clinically material, and where elective surgery is best postponed until control improves.14

Table 1 · HbA1c band → risk profile and recommendation
HbA1c bandRisk profileRecommendationEvidence
≤ 7%
Well-controlled
(often acceptable to ~8%)		 Survival comparable to non-diabetic (~96–97% at 1 yr); healing essentially normal Proceed with routine perioperative care, anti-infective measures, and standard follow-up Syst. review / meta-analysis
7 – 8%
Moderately controlled		 Acceptable but slightly elevated risk of delayed healing and infection Proceed if stable; optimize control where feasible; reinforce anti-infective protocol; closer follow-up and a more conservative loading timeline Syst. review
> 8%
Poorly controlled		 Delayed healing, impaired infection control, accelerated marginal bone loss; worsening as HbA1c climbs Defer elective surgery; refer to physician for medical optimization; re-stage once control improves Syst. review
Day-of glucose
Acute factor		 Captures acute hyperglycemia a months-old HbA1c will miss Confirm acceptable perioperative capillary glucose; postpone if markedly hyperglycemic regardless of band Consensus
Infection control
All bands		 Diabetic wound healing and host defense are impaired in proportion to control Asepsis, chlorhexidine, antibiotic prophylaxis where indicated, and close monitoring of healing for every patient Consensus
✦ Clinical pearl · Read the average and the moment

HbA1c is a two-to-three-month average and will not reveal an acutely hyperglycemic patient on the day of surgery — nor a recent destabilization since the last blood draw. Pair a recent HbA1c (ideally within ~3 months) with a day-of-surgery capillary glucose. A reassuring HbA1c does not license operating through a markedly elevated point-of-care reading.

§3.4.3 — Decision pathway

From band to pathway, at the chairside

The three bands map to three pathways. The selector below reproduces that logic interactively: choose the patient's current glycemic-control band to see the corresponding pathway, its rationale, and the concrete perioperative steps. As with every threshold in this chapter, the cut-offs are guidance rather than absolutes — individualize each decision in coordination with the patient's physician.

Tap the patient's current glycemic-control band.
Step 1 — What is the most recent HbA1c?

▲ Common pitfalls
  • Refusing implant therapy on the diagnosis alone. A well-controlled patient is a standard-risk patient; blanket denial is not evidence-based.
  • Trusting a stale HbA1c. A value many months old may no longer reflect current control, particularly after medication changes or intercurrent illness.
  • Operating on a well-controlled HbA1c while ignoring a markedly elevated day-of-surgery glucose, or while an active oral infection is untreated.
  • Deferring indefinitely without a plan. "Defer" means refer for optimization, set an HbA1c target, and schedule re-testing — not abandon the patient.
§3.4.4 — Perioperative care

What applies to every diabetic patient

Independent of band, four threads run through the perioperative management of the diabetic implant patient. Glucose stability on the day of surgery is confirmed by point-of-care testing and protected by sensible scheduling — appointments timed to the patient's meal and medication rhythm, and procedures kept efficient to avoid prolonged fasting that risks hypoglycemia. Anti-infective rigor — asepsis, chlorhexidine, and perioperative antibiotic prophylaxis where indicated — compensates for the impaired host defense that accompanies hyperglycemia; the companion antibiotic-prophylaxis chapter develops the indications in detail.5

Third, healing surveillance is intensified: the diabetic interface integrates more slowly, so a more conservative loading timeline and closer follow-up are reasonable defaults, with the patient counseled that stable glycemia during the osseointegration window is part of their responsibility. Fourth, and underpinning all of the above, is physician coordination. Glycemic optimization is a medical task; the dentist's role is to read the control band, time the surgery to it, and partner with the patient's physician on targets and perioperative management before and after the procedure.1

✦ Clinical pearl · Defer is an active plan, not a refusal

When HbA1c exceeds 8%, "defer" should be operationalized: refer to the physician with a stated target (commonly a return to the moderate or well-controlled band), manage any active oral infection and disease in the interim, set a re-test interval, and bring the patient back into the algorithm once control improves. A deferral with a date and a target is a treatment plan; a deferral without one is an abandonment.

§3.4.5 — Glossary

Key terms

HbA1c (glycated hemoglobin)
The fraction of hemoglobin that is glycated, reflecting average blood glucose over the preceding ~2–3 months; the principal gate for stratifying glycemic control.
Well-controlled diabetes
HbA1c ≤ 7% (often considered acceptable up to ~8%); implant survival comparable to non-diabetic patients.
Moderately controlled diabetes
HbA1c between 7% and 8%; generally acceptable for surgery with a modest excess risk and a case for optimization.
Poorly controlled diabetes
HbA1c > 8%; associated with delayed healing, impaired infection control, and worse peri-implant outcomes; elective surgery is generally deferred.
Day-of-surgery glucose
Point-of-care capillary blood glucose measured perioperatively to detect acute hyperglycemia not captured by HbA1c.
Dose-response trend
The observed gradient by which peri-implant clinical and radiographic outcomes deteriorate progressively as HbA1c increases, rather than at a single threshold.
Advanced glycation end-products (AGEs)
Glucose-modified proteins and lipids that accumulate in hyperglycemia, promoting chronic inflammation and impairing collagen and bone metabolism.
Marginal bone loss
Loss of crestal bone around an implant; a key radiographic peri-implant outcome adversely affected by poor glycemic control.
§3.4.S — Self-test

Fellowship & board preparation

1. The single most important determinant of dental implant outcomes in a patient with diabetes is:
B is correct. Across systematic reviews, outcomes track the degree of control, not the diagnosis. Well-controlled patients achieve survival comparable to non-diabetic patients; risk rises in a dose-dependent way as control worsens.
2. Which HbA1c value best defines the conventional upper limit of the well-controlled band?
B is correct. Well-controlled is conventionally HbA1c ≤ 7%, with many sources accepting up to ~8%; 7–8% is moderate and >8% is poorly controlled.
3. An HbA1c between 7% and 8% places a patient in which band?
B is correct. The 7–8% range defines moderate control: generally acceptable for surgery but warranting optimization where feasible and heightened vigilance.
4. For a patient with HbA1c > 8% presenting for an elective implant, the most appropriate action is to:
B is correct. >8% is poorly controlled, with elevated risk of delayed healing and infection. Defer the elective procedure and refer to the physician to improve control, then re-stage.
5. Approximately what implant survival is reported at one year for well-controlled diabetic patients?
C is correct. Pooled one-year survival for well-controlled diabetes is roughly 96–97%, statistically comparable to non-diabetic cohorts — the basis for treating these patients as standard-risk.
6. HbA1c reflects average blood glucose over approximately what period?
C is correct. Glycated hemoglobin reflects average glycemia over the preceding ~2–3 months, which is why it is paired with a day-of-surgery glucose to catch acute changes.
7. Why is a day-of-surgery capillary glucose obtained in addition to a recent HbA1c?
A is correct. A reassuring average does not exclude acute hyperglycemia on the day; a markedly elevated point-of-care glucose can warrant postponement regardless of band.
8. The relationship between rising HbA1c and peri-implant outcomes is best described as:
B is correct. There is moderate evidence of a dose-response trend: clinical and radiographic outcomes decline progressively as HbA1c increases, rather than at one discrete cut-off.
9. Which two complications dominate the risk profile of poorly controlled diabetes for implants?
B is correct. Chronic hyperglycemia impairs healing and host defense, so delayed osseointegration, infection, and accelerated marginal bone loss define the diabetic risk profile.
10. Which measures apply to diabetic implant patients across all glycemic bands?
B is correct. Day-of-surgery glucose confirmation and anti-infective rigor (asepsis, chlorhexidine, prophylaxis where indicated) are universal, not band-specific.
11. A patient with HbA1c 7.4% and stable control who cannot improve further is best managed by:
B is correct. Moderate, stable control is generally acceptable. If further optimization is not achievable, proceed with closer follow-up and a more conservative timeline rather than refusing care.
12. The accumulation of advanced glycation end-products in hyperglycemia principally contributes to impaired healing by:
A is correct. AGEs sustain a pro-inflammatory state and degrade collagen and bone metabolism, contributing to the delayed healing and impaired host defense seen in poor control.
13. "Defer" for a poorly controlled patient is best operationalized as:
B is correct. A deferral is an active plan: refer to the physician with a target, manage active oral disease in the interim, set a re-test interval, and re-stage once control improves.
14. Which statement about diabetes as a contraindication to implants is most accurate?
C is correct. Well-controlled diabetes is not a contraindication; poor control raises risk and is a relative, modifiable contraindication addressed by optimization.
15. For optimal currency, a recent HbA1c used for surgical planning should ideally be from within approximately:
B is correct. Because HbA1c reflects the prior ~2–3 months, a value within about 3 months best represents current control; older values may be stale after medication changes or illness.
16. Appointment scheduling for a diabetic patient should aim chiefly to:
B is correct. Timing appointments to the patient's meal and medication rhythm, and keeping procedures efficient, avoids both prolonged-fasting hypoglycemia and uncontrolled hyperglycemia.
17. In the moderately controlled band, a reasonable adjustment to the restorative plan is:
B is correct. Slightly slower, less predictable healing favors a more conservative loading timeline and closer monitoring rather than acceleration.
18. The clinician's role relative to the patient's physician in glycemic management is best described as:
B is correct. Glycemic optimization is a medical task. The dentist stratifies by HbA1c, times surgery to control, and partners with the physician on targets and perioperative management.
19. Which finding should prompt postponement even when the HbA1c is reassuring?
B is correct. Acute hyperglycemia on the day, or an active oral infection, can warrant postponement irrespective of a favorable HbA1c.
20. Anti-infective measures are emphasized in diabetic patients principally because hyperglycemia:
B is correct. Hyperglycemia compromises neutrophil-mediated defense and healing in proportion to control, so asepsis, chlorhexidine, and prophylaxis where indicated are reinforced across all bands.
1. A new patient with type 2 diabetes wants implants. Walk me through how you decide whether to proceed.
Model answer. I begin from the principle that outcomes track glycemic control rather than the diagnosis, so my decision turns on a recent HbA1c, ideally within about three months, read alongside the day-of-surgery glucose. If HbA1c is well-controlled — at or below 7%, with many sources accepting up to about 8% — I treat the patient as standard-risk and proceed with routine perioperative care and rigorous infection control. If it is moderate, 7 to 8%, I proceed if control is stable but optimize where feasible first, reinforce the anti-infective protocol, and plan a more conservative loading timeline with closer follow-up. If it is poor, above 8%, I defer the elective procedure and refer to the physician for optimization, then re-stage once control improves. Throughout, I coordinate with the physician and confirm there is no acute hyperglycemia or active oral infection on the day.
Examiner follow-ups:
  • What if the HbA1c is six months old?
  • How would a high day-of-surgery glucose change your plan despite a good HbA1c?
2. Why does glycemic control, rather than the diagnosis of diabetes, drive implant outcomes? Justify from the biology.
Model answer. Chronic hyperglycemia, not the label, is what perturbs the healing cascade. It drives the accumulation of advanced glycation end-products that stiffen collagen and sustain a pro-inflammatory state; it impairs the M1-to-M2 macrophage transition, blunts angiogenesis, suppresses osteoblast function while favoring osteoclastic resorption, and compromises neutrophil-mediated infection control. These are exactly the early osseointegration steps an implant depends on, so a patient whose glucose is well controlled has a near-normal healing environment and survival comparable to a non-diabetic patient, whereas a poorly controlled patient carries a dose-dependent excess of delayed healing, infection, and marginal bone loss. That is why we stratify and time surgery by HbA1c rather than by diagnosis.
Examiner follow-ups:
  • Which single mechanistic step would you most want to protect, and how?
  • How does this rationale shape your loading timeline?
3. State the HbA1c bands and the survival evidence that underpins treating well-controlled patients as standard-risk.
Model answer. The conventional bands are well-controlled at or below 7%, with acceptance often extending to about 8%; moderately controlled at 7 to 8%; and poorly controlled above 8%. The evidence that justifies standard-risk handling of the well-controlled patient comes from systematic reviews and meta-analyses reporting one-year survival of roughly 96 to 97% and multi-year survival comparable to non-diabetic cohorts when HbA1c is below about 8%. Importantly the literature also shows a dose-response gradient, with peri-implant clinical and radiographic outcomes declining progressively as HbA1c rises, which is why moderate control invites optimization and poor control invites deferral. I always caveat that exact thresholds vary across guidelines and the evidence is heterogeneous, so I individualize with the physician.
Examiner follow-ups:
  • What does "dose-response" imply for a patient at 9% versus 11%?
  • How strong is the evidence, and what are its limitations?
4. A patient presents with HbA1c of 9.5%. Take me through your management, including how you handle the conversation and the follow-up.
Model answer. At 9.5% the patient is poorly controlled, with an elevated risk of delayed healing, impaired infection control, and accelerated marginal bone loss, so I defer the elective placement rather than proceed. I explain that this is not a refusal but a sequencing decision: well-controlled diabetes does implant excellently, and our goal is to get them there. I refer to their physician for medical optimization with a stated target — typically a return to the moderate or well-controlled band — and I set a concrete re-test interval for HbA1c. In the interim I manage any active oral infection and disease and reinforce oral hygiene, both because infection control matters and because it improves the eventual surgical field. Once control reaches an acceptable band, I bring the patient back into the algorithm, confirm a recent HbA1c and day-of-surgery glucose, and proceed with reinforced anti-infective measures and a conservative timeline. The deferral always carries a target and a date.
Examiner follow-ups:
  • What target HbA1c would you set, and why?
  • What would you do if the patient cannot achieve better control despite effort?
  • How do you document this decision?
5. What perioperative measures apply to every diabetic implant patient regardless of band, and what is your role versus the physician's?
Model answer. Four things apply across every band. First, glucose stability on the day — I confirm an acceptable point-of-care reading and schedule to the patient's meal and medication timing, keeping procedures efficient to avoid both fasting hypoglycemia and uncontrolled hyperglycemia. Second, anti-infective rigor — asepsis, chlorhexidine, and antibiotic prophylaxis where indicated — to compensate for impaired host defense. Third, intensified healing surveillance with a more conservative loading timeline and closer follow-up, counseling the patient that stable glycemia during osseointegration is part of their responsibility. Fourth, physician coordination underpins all of it: glycemic optimization is a medical task, so my role is to read the control band, time surgery to it, and partner with the physician on targets and perioperative management before and after surgery. I do not independently manage diabetes medications.
Examiner follow-ups:
  • When is antibiotic prophylaxis indicated here?
  • How would you counsel the patient on their role during healing?
  • What would you communicate to the physician in your referral?
§3.4 — References

References

  1. Naujokat H, Kunzendorf B, Wiltfang J. Dental implants and diabetes mellitus — a systematic review. Int J Implant Dent. 2016;2(1):5. doi:10.1186/s40729-016-0038-2
  2. James Y, Butt WMM, Shahid H, Ahmad S, Imran MTB, Anthony N. Success Rates of Dental Implants in Patients With Diabetes: A Systematic Review. Cureus. 2024;16(12):e76361. doi:10.7759/cureus.76361
  3. Wagner J, Spille JH, Wiltfang J, Naujokat H. Systematic review on diabetes mellitus and dental implants: an update. Int J Implant Dent. 2022;8(1):1. doi:10.1186/s40729-021-00399-8
  4. Eskow CC, Oates TW. Dental Implant Survival and Complication Rate over 2 Years for Individuals with Poorly Controlled Type 2 Diabetes Mellitus. Clin Implant Dent Relat Res. 2017;19(3):423–431. doi:10.1111/cid.12465
  5. Cosola S, Butera A, Hailu Zergaw H, et al. Glycemic Control and Implant Stability in Patients with Type II Diabetes: Narrative Review. Healthcare (Basel). 2025;13(5):449. doi:10.3390/healthcare13050449

HbA1c cut-offs vary across guidelines and the underlying evidence is heterogeneous; values cited reflect the conventional bands used in the implant literature. Evidence grades: Systematic review Consensus Preclinical.

About this chapter

This chapter is part of Osseo IQ — a clinical reference for implant dentistry. Content is sourced from consensus statements, systematic reviews, and primary literature; each key recommendation carries an evidence grade, and every page records its review date. Material is reviewed on a rolling annual cycle.

How to cite: Khuu T, ed. Diabetes: Perioperative Management. In: Osseo IQ, 1st ed. §3.4. June 2026. Accessed [date]. [URL]

Compiled by: Tan Khuu, DDS — Doctor of Dental Surgery and a licensed dentist in California and South Carolina. Osseo IQ summarizes published evidence and clinical guidelines and is not a substitute for individual clinical judgment. Image credits: Figures 1–3 original schematic illustrations © Osseo IQ, 2026.

For licensed clinicians — educational use only. This chapter summarizes published evidence and is not a substitute for individual clinical judgment, examination, or the standard of care in your jurisdiction. HbA1c cut-offs vary across guidelines and the evidence is heterogeneous. Coordinate with the patient's physician on glycemic optimization and perioperative management before and after surgery. Verify drug doses, devices, and protocols against current manufacturer instructions and local guidelines.

© 2026 Osseo IQ · Edition 1.0 · Chapter 3 Patient Selection & Medical Risk · §3.4 · Last reviewed June 2026